Navigation Links
Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
Date:12/6/2007

SAN FRANCISCO, Dec. 6 /PRNewswire/ -- Epiphany Biosciences announced today, the initiation of a Phase 2 clinical trial with valomaciclovir (EPB-348) for the treatment and management of acute infectious mononucleosis. Currently, there are no approved therapeutics for the treatment for this debilitating condition or any other disease caused by the Epstein-Barr virus (EBV)

"Valomaciclovir has shown a broad spectrum of anti-viral activity, including inhibition of viral replication of herpes zoster and EBV," said Fred Volinsky, MD, Chief Executive Officer. "EBV has been implicated in a number of chronic and transplant-related diseases. This initial study in acute mononucleosis will set the stage for broader indications involving EBV as an etiologic agent. We are pleased to be working with the University of Minnesota on this important project".

"EBV is a highly prevalent virus, with up to 95% of middle-aged adults possessing evidence of viral exposure according to CDC surveillance data," stated Brian Murphy, MD, Chief Medical Officer. "Mononucleosis can severely undermine quality-of-life and the acute EBV infection may lead to other long-term medical sequelae. This double-blind, placebo-controlled, clinical trial will examine fluctuations in viral load as influenced by valomaciclovir as well as assess symptom scores."

"Our laboratory has found valomaciclovir to be a very potent anti-viral agent against EBV", reported Dr. Henry H. Balfour, Jr., Professor of Pediatrics and Laboratory Medicine and Pathology at the University of Minnesota, who is principal investigator for the study. "If this proof of concept study is successful, further large scale studies are warranted. We urgently need a solution for this disease that can severely impact the lives of young adults."

The acute mononucleosis study at the University of Minnesota will mark the first of several planned studies of valomaciclovir against EBV related diseases. Comparative anti-EBV potency data were presented by Professor Balfour's team at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago in September. A manuscript containing additional data confirming the unique susceptibility of EBV to valomaciclovir will be submitted to a peer-reviewed scientific journal shortly.

About Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for infectious disease. Epiphany is currently conducting a large Phase 2b study examining the safety and efficacy of valomaciclovir against herpes zoster infection.

Epiphany was founded by a world-class virology team, including two Lasker Award winners. Epiphany is located in San Francisco, CA. Additional information on Epiphany Biosciences may be obtained at the company website http://www.epiphanybio.com or by contacting company representatives: Fred G. Volinsky MD, CEO 415.765.7193


'/>"/>
SOURCE Epiphany Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):